Mirai Bio
Mirai Bio offers an open end-to-end platform that accelerates development and delivery of genetic medicines for biotech partners. It uses AI and machine learning, including generative design of cargo and high-throughput in vivo multiplexing, to optimize therapeutic payloads and target selection. The platform integrates advanced delivery mechanisms and manufacturing capabilities to translate candidates from concept to clinic. Mirai Bio operates as a B2B development partner for biotech companies focused on genetic therapies and enables access to cell types previously difficult to reach.
Mirai Bio
Mirai Bio offers an open end-to-end platform that accelerates development and delivery of genetic medicines for biotech partners. It uses AI and machine learning, including generative design of cargo and high-throughput in vivo multiplexing, to optimize therapeutic payloads and target selection. The platform integrates advanced delivery mechanisms and manufacturing capabilities to translate candidates from concept to clinic. Mirai Bio operates as a B2B development partner for biotech companies focused on genetic therapies and enables access to cell types previously difficult to reach.
TL;DR
Founded: 2021
Headquarters: Cambridge, Massachusetts
Business model: B2B development partner for biotech genetic medicines
Tech focus: AI/ML-driven platform for design, delivery, and manufacturing of genetic medicines
Notable investor / founder: Flagship Pioneering
Company Overview
Problem Domain
Genetic medicine development — improving design and delivery to reach diverse tissues and cell types and accelerating clinical translation.
Founded
2021
Industry
Biotechnology
Tech Stack
Funding Track Record
50000000
Initial commitment reported at company announcement.
Strategic partnership announced that included a direct investment.
Investor Signal
“Flagship Pioneering (founder and lead investor); strategic partnership and direct investment from Thermo Fisher Scientific announced May 20, 2025.”